Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.

ABSTRACT:

Importance

Muvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effect of longer administration of muvalaplin on lipoprotein(a) levels in individuals at high cardiovascular risk remains uncertain.

Objectives

To determine the effect of muvalaplin on lipoprotein(a) levels and to assess safety and tolerability.

Design, setting, and participants

Phase 2, placebo-controlled, randomized, double-blind trial enrolling 233 participants with lipoprotein(a) concentrations of 175 nmol/L or greater with atherosclerotic cardiovascular disease, diabetes, or familial hypercholesterolemia at 43 sites in Asia, Europe, Australia, Brazil, and the United States between December

SUBMITTER: Nicholls SJ 

PROVIDER: S-EPMC11574718 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature